会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
    • 氨基烷基取代的5,6,7,8-四氢-9H-吡啶并[2,3-b]吲哚衍生物
    • US06472402B1
    • 2002-10-29
    • US09408613
    • 1999-09-30
    • Raymond F. HorvathJames W. DarrowGeorge D. Maynard
    • Raymond F. HorvathJames W. DarrowGeorge D. Maynard
    • C07D47104
    • C07D471/04C07D487/04
    • Disclosed are compounds of the formula: wherein Ar, R1, W, X and m are substituents as defined herein. These compounds are modulators of CRF receptors and are therefore useful for treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals, comprising: administering to the mammal a therapeutically effective amount of a compound of Formula I.
    • 公开了下式的化合物:其中Ar,R 1,W,X和m是如本文所定义的取代基。这些化合物是CRF受体的调节剂,因此可用于治疗情感障碍,焦虑症,抑郁症,头痛,肠易激综合征, 创伤性应激障碍,核上性麻痹,免疫抑制,阿尔茨海默病,胃肠道疾病,神经性厌食症或其他进食障碍,药物成瘾,药物或酒精戒断症状,​​炎症性疾病,心血管或心脏相关疾病,生育问题,人类免疫缺陷病毒感染, 出血性压力,肥胖症,不育症,头部和脊髓创伤,癫痫,中风,溃疡,肌萎缩性侧索硬化,低血糖或疾病,其治疗可以通过拮抗CRF来实现或促进,包括但不限于由 CRF,在哺乳动物中,包括:向哺乳动物施用治疗有效量的ac 一级方程式
    • 4. 发明授权
    • Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino [2, 3-B] indole and 5,6,7,8-tetrahydro-9H-pyrimidino [4, 5-B] indole derivatives: CRF1 specific ligands
    • 氨基烷基取代的5,6,7,8-四氢-9H-吡啶并[2,3-B]吲哚和5,6,7,8-四氢-9H-嘧啶并[4,5-B]吲哚衍生物:CRF1特异性配体
    • US06291473B1
    • 2001-09-18
    • US09283723
    • 1999-04-01
    • Raymond F. HorvathJames W. DarrowGeorge D. Maynard
    • Raymond F. HorvathJames W. DarrowGeorge D. Maynard
    • A61K31405
    • C07D471/04C07D487/04
    • Disclosed are compounds of the formula: wherein Ar, R1, W, X and m are substituents as defined herein. These compounds are modulators of CRF receptors and are therefore useful for treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals, comprising: administering to the mammal a therapeutically effective amount of a compound of Formula I.
    • 公开了下式的化合物:其中Ar,R 1,W,X和m是如本文所定义的取代基。这些化合物是CRF受体的调节剂,因此可用于治疗情感障碍,焦虑症,抑郁症,头痛,肠易激综合征, 创伤性应激障碍,核上性麻痹,免疫抑制,阿尔茨海默病,胃肠道疾病,神经性厌食症或其他进食障碍,药物成瘾,药物或酒精戒断症状,​​炎症性疾病,心血管或心脏相关疾病,生育问题,人类免疫缺陷病毒感染, 出血性压力,肥胖症,不育症,头部和脊髓创伤,癫痫,中风,溃疡,肌萎缩性侧索硬化,低血糖或疾病,其治疗可以通过拮抗CRF来实现或促进,包括但不限于由 CRF,在哺乳动物中,包括:向哺乳动物施用治疗有效量的ac 一级方程式
    • 6. 发明授权
    • Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
    • 吡咯并吡啶,吡咯并嘧啶和相关的杂环化合物
    • US08633193B2
    • 2014-01-21
    • US13014066
    • 2011-01-26
    • Jun YuanPeter HrnciarQin GuoGeorge D. Maynard
    • Jun YuanPeter HrnciarQin GuoGeorge D. Maynard
    • A61K31/519C07D487/04A61P37/00A61P37/06A61P11/06A61P17/06
    • C07D471/04
    • Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds analogues of the formula: wherein R, R2, R5, E, Z1, Z3, Z4, and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds of the invention bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds, which are useful as probes for the localization of C5a receptors.
    • 吡咯并 - 吡啶,吡咯并 - 嘧啶和相关的杂环化合物,其分子式如下:其中R,R 2,R 5,E,Z 1,Z 3,Z 4和Ar如本文所定义。 这些化合物是C5a受体的配体。 本发明优选的吡咯并 - 吡啶,吡咯并 - 嘧啶和相关杂环化合物以高亲和力结合C5a受体,并在C5a受体上表现出中性拮抗剂或反向激动剂活性。 本发明还涉及包含这些化合物的药物组合物,以及这些化合物在治疗各种炎性,心血管和免疫系统疾病中的用途。 此外,本发明提供了标记的吡咯并 - 吡啶,吡咯并 - 嘧啶和相关杂环化合物,其可用作C5a受体定位的探针。
    • 8. 发明授权
    • Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors
    • 咪唑并吡啶类和相关衍生物作为缓激肽B2受体的选择性调节剂
    • US06420365B1
    • 2002-07-16
    • US09765159
    • 2001-01-17
    • John M. PetersonAlan HutchisonKenneth ShawKevin HodgettsGeorge D. MaynardRichard Lew
    • John M. PetersonAlan HutchisonKenneth ShawKevin HodgettsGeorge D. MaynardRichard Lew
    • A61K31435
    • C07D471/04
    • Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein A, B, C, D, Y, R1, R3, R4, R5, and R6 are variables defined herein, which compounds are modulators of Bradykinin B2 receptors. These compounds are useful in the diagnosis and treatment of renal diseases, heart failure, hypertension, Meniere's disease, vaginal inflammation and pain, peripheral circulatory disorders, climacteric disturbance, retinochoroidal circulatory disorders, myocardial ischemia, myocardial infarction, postmyocardial infarction syndrome, angina pectoris, restenosis after percutaneous transluminal coronary angioplasty, hepatitis, liver cirrhosis, pancreatitis, ileus, diabetes, diabetic complications, male infertility, glaucoma, pain, asthma, and rhinitis and for the increase of permeability of the blood-brain barrier or the blood-brain-tumor barrier.
    • 公开了下式的化合物或其药学上可接受的无毒性盐,其中A,B,C,D,Y,R 1,R 3,R 4,R 5和R 6是本文定义的变量,该化合物是缓激肽B2受体的调节剂 。 这些化合物可用于诊断和治疗肾脏疾病,心力衰竭,高血压,梅尼埃病,阴道炎症和疼痛,外周循环障碍,更年期障碍,视网膜循环障碍,心肌缺血,心肌梗死,心肌梗死后综合征,心绞痛, 经皮腔内冠状动脉血管成形术,肝炎,肝硬化,胰腺炎,肠梗阻,糖尿病,糖尿病并发症,男性不育症,青光眼,疼痛,哮喘和鼻炎的再狭窄,以及增加血脑屏障或血脑屏障的渗透性, 肿瘤屏障。